Tazemetostat
Tazemetostat is an orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyltransferase EZH2, with potential antineoplastic activity. Upon oral administration, Tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27).
| Catalog Number | T1788 |
| Alternative Name(s) | E-7438 , EPZ6438 |
| Research Area | Chromatin/Epigenetic |
| Molecular Formula | C34H44N4O4 |
| CAS# | 1403254-99-8 |
| Purity | 99.72% |
| SMILES | CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1 |
| Size | 100 mg |
| Supplier Page | https://www.targetmol.com/compound/Tazemetostat |
| Additional Information | https://www.targetmol.com/datasheet/T1788 |